Phase Ib/II Trial Evaluating the Safety, Tolerability and Immunological Activity of Durvalumab (MEDI4736) (Anti-PD-L1) Plus Tremelimumab (Anti-CTLA-4) Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Phase of Trial: Phase I/II
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Adverse reactions
- Acronyms MEDITREME
- 21 Sep 2017 Status changed from not yet recruiting to recruiting.
- 15 Sep 2017 Planned End Date changed from 1 Sep 2020 to 29 Aug 2020.
- 15 Sep 2017 Planned primary completion date changed from 1 Sep 2019 to 29 Aug 2019.